An evaluation of the impact of oral magnesium lactate on the corrected qt interval of patients receiving sotalol or dofetilide to prevent atrial or ventricular tachyarrhythmia recurrence

Annals of Noninvasive Electrocardiology

Volumn 11, Issue 2, 2006, Pages 163-169

  McBride, Brian F ^a,c   Min, Bokyung ^a,c   Kluger, Jeffrey ^b,c   Guertin, Danette ^c   Henyan, Nickole N ^a,c   Coleman, Craig I ^a,c   Silver, Burton B ^d   White, C Michael ^a,c  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c HARTFORD HOSPITAL   (United States)

^d Intracellular Diagnostics Inc   (United States)

Author keywords

Arrhythmia; Dofetilide; Magnesium; QTc interval; Sotalol

Indexed keywords

DIURETIC AGENT; DOFETILIDE; MAGNESIUM; MAGNESIUM 1 LACTATE; PLACEBO; SOTALOL; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; ELECTROCARDIOGRAM; EVALUATION; FEMALE; FUNCTION TEST; HEART ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; INTRACELLULAR SPACE; MAGNESIUM DEFICIENCY; MALE; MEASUREMENT; PRIORITY JOURNAL; QT INTERVAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RR INTERVAL; SUPRAVENTRICULAR TACHYCARDIA; TREATMENT DURATION; X RAY ANALYSIS;

ADMINISTRATION, ORAL; AGED; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; CHI-SQUARE DISTRIBUTION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; LACTIC ACID; MAGNESIUM COMPOUNDS; MALE; PHENETHYLAMINES; RECURRENCE; SOTALOL; STATISTICS, NONPARAMETRIC; SULFONAMIDES; TREATMENT OUTCOME;

EID: 33645302935     PISSN: 1082720X     EISSN: 1542474X     Source Type: Journal    
DOI: 10.1111/j.1542-474X.2006.00098.x     Document Type: Article

References (17)

1. Mc Evoy GK ed. American Hospital Formulary Service Drug Information. Bethesda American Society of Health-Systems Pharmacists 2002 1529 1530.
2. Bednar MM Harrigan EP Anziano RW et al.. The QT interval. Prog Cardiovasc Dis 2001 104 43 1 45.
3. Lahmann MH Hardy S Archibald D et al.. Sex differences in risk of torsade de pointes with d,l-sotalol. Circulation 1996 94 2534 2541.
4. Torp-Pedersen C Moller M Bloch-Thompsen PE et al.. for the Danish Investigators of Arrhythmia and Mortality on Dofetilide Study Group. Dofetilide in patients congestive heart failure and left ventricular dysfunction. N Engl J Med 1999 341 857 865.
5. Pedersen OD Bagger H Keller N et al. Efficacy of dofetilide in the treatment of atrial fibrillation with reduced left ventricular function: A Danish investigation of arrhythmia and mortality on dofetilide (DIAMOND) substudy. Circulation 2001 104 292 296.
6. Brendrop B Elming H Jun L et al.. QTc interval as a guide to select those patients with congestive heart failure and reduced left ventricular systolic function who will benefit from antiarrhythmic treatment with dofetilide. Circulation 2001 103 1422 1427.
7. The AFFIRM Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002 347 1825 1833.
8. White CM Xie J Chow MSS et al.. Prophylactic magnesium to decrease the arrhythmogenic potential of Class III antiarrhythmic agents in a rabbit model. Pharmacotherapy 1999 19 635 640.
9. Caron MF Kluger J Tsikouris JP et al.. The effects of intravenous magnesium sulfate on the QT interval in patients receiving ibutilide. Pharmacotherapy 2003 23 296 300.
10. Kalus JS Spencer AP Tsikouris JP et al.. Impact of prophylactic intravenous magnesium on the efficacy of ibutilide for conversion of atrial fibrillation or flutter. Am J Health Syst Pharm 2003 60 2308 2312.
11. Mag-Tab SR (Magnesium l -Lactate) package insert. Roanoke TX Niche Pharmaceuticals 2002.
12. Tran HT Fan C Tu WQ et al.. QT measurement, a comparison of three simple methods. Ann Noninvasive Electrocardiol 1998 3 228 231.
13. Antzelevitch C Shimizu W Yan GX et al.. Cellular basis for QT dispersion. J Electrocardiol 1998 30 Suppl. 168 175.
14. Yamaguchi M Shimizu M Ino H et al.. T wave peak-to-end interval and QT dispersion in acquired long QT syndrome: A new index for arrhythmogenicity. Clin Sci (Lond) 2003 150 671 676.
15. Wei SK Hanlon SU Haigney MCP. Beta-adrenergic stimulation of pig myocytes with decreased cytosolic free magnesium prolongs the action potential and enhances triggered activity. J Cardiovasc Electrophysiol 2002 13 587 592.
16. Michailova AP Belik ME McCulloch AD. Effects of magnesium on cardiac excitation-contraction coupling. J Am Coll Nutr 2004 23 514S 517S.
17. Moss AJ Schwartz PJ Crampton RS et al.. The long QT syndrome: Prospective longitudinal study of 328 families. Circulation 1991 84 1136 1144.